It seems well established that CpG oligonucleotides Th1 biased adjuvant activity can be improved when closely associated with a variety of antigens in, for example, microparticles. In this context, we prepared 1-µm near non-charged PLGA 502 or PLGA 756 microparticles that loaded with high efficiency an antigen (50% ovalbumin 
Introduction
Current studies in the field of vaccination are based on subcellular compounds of pathogens [1] [2] [3] , avoiding the potential pathogenicity of using attenuated organisms.
However, the lack of immunogenicity applies for adjuvants and/or immunomodulators.
Between the adjuvants described in the literature only aluminium hydroxide (alum) and the emulsion MF59 have been approved for human applications due to their confirmed efficacy and safety [4] . In spite of being the most used adjuvant, alum is a pro-Th2 response enhancer. This outcome is not suitable for some disorders like intracellular infections and allergy [5, 6] . Moreover, the possibility of some undesirable side effects (including hypersensibility to aluminium [7] , granuloma [8] and the relationship between the accumulation of aluminium and the Alzheimer disease [9] ) have been reported. Consequently, the search for novel adjuvants remains a health priority.
Microparticles have been widely reported in the literature as carriers for antigen delivery [10] [11] [12] . Poly(lactic-co-glycolic) acid (PLGA) appears as an attractive candidate for the fabrication of microparticles since its use in resorbable sutures [13] for humans has been approved by the FDA. The protection that microparticles provide to the antigen and the improvement in the uptake by the antigen presenting cells (APC) result in the enhancement of the antigen poor immunogenicity [14] . Besides, the nature of degradation of the carrier maintains a sustained release [15] throughout the time which would be in concordance with a few shot protocol of vaccination.
Pathogen associated molecular patterns (PAMP) have been confirmed as potent immunomodulators due to their interaction with the APC. Their signalization pathway starts in Toll-like receptors (TLR), specific for each PAMP, and ends triggering the immune response. In the case of oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN), the association with their endosomal specific receptor (TLR-9) [16, 17] initiates a complex molecular cascade which encourages the transcription of pro-inflammatory cytokines encoding genes, such as IL-12 and tumor necrosis factor (TNF) [18] . Afterwards, the presence of these molecules in the environment potentates the differentiation of naïve Th0 cells into Th1 and cytotoxic T lymphocytes [19] . Thus, the deviation exerted in the immune response could be taken in advantageous to coadminister antigens as well as CpG sequences, leading to a potent antigen-specific Th1 type response and being a promising strategy for a wide range of diseases, such as bacterial infections [20] , cancer [21, 22] and allergy [23] .
In vivo, both CpG sequences and antigens have been administered directly in a physical mixture or after their covalent association [24] . Also, CpG motifs have been combined with drug delivery systems in a solution [25] but all these strategies could result in CpG and/or antigen damaging by enzymes in the biological environment.
Therefore, the association of both antigen and oligonucleotide into the same carrier is supposed to offer several advantages [25] [26] [27] [28] . Despite CpG sequences are under clinical trials, some authors have reported adverse effects such as splenomegaly, lymphadenopathy [29] or the activation of autoimmune responses [30] in animal models after the administration of high doses of CpG motifs (over than 100 µg). In this context, the particle would protect both molecules from degradation so it would not be necessary to administer a high amount of CpG sequences. Besides, the particulated antigen and immunomodulator would be recognized by the immune system like a "danger signal" so the phagocytosis/endocytosis would be improved. In consequence, both molecules would interact with the same APC, displaying a strong antigen specific immune response.
In this context, the association of CpG sequences with positive molecules has been described as a successful strategy to load both molecules into the same particle [31, 32] . The milestone of this idea is the counterbalancing of the CpG negative charges and the reduction of its hidrophylicity. In our work conditions, preliminary studies have confirmed that the absence of cationic molecules lead to insignificant CpG encapsulation efficiency.
The aim of the present study was to co-encapsulate both ovalbumin (OVA), as an antigen model, and CpG sequences into PLGA 502 and 756 microparticles using a recently described emulsion and solvent evaporation method called Total Recirculation One Machine System (TROMS). For this purpose, chitosan was used to form a complex with the oligonucleotide, which would decrease its hydrophylicity achieving a high CpG pay-load. Moreover, the immunostimulatory potency of the CpG loaded microparticles was analysed in vitro after incubation with bone marrow-derived dendritic cells (BMDC) and in vivo conditions after immunizing BALB/c mice by intradermal route.
Materials and methods

Materials
The copolymers formed by lactic and glycolic acid, Resomer 
Microparticle fabrication
Microparticles (MP) were fabricated by the solvent evaporation method using TROMS [33, 34] . Briefly, the polymer dissolved in methylene chloride (50 mg PLGA 502 or 756, 4% w/v) was injected under a turbulent regime (50 mL/min) through a needle with an inner diameter of 0.17 mm onto a solution of Pluronic ® F68 (6%) and chitosan containing ovalbumin (3 mg) and/or CpG sequences (300 nmol, approximately), depending on the formulation. Then, this W 1 /O emulsion was forced to circulate through the system for 2 min in order to homogenize the droplet size.
Afterwards, this emulsion was injected onto the outer water phase, PVA (0.5% w/v), maintaining the pumping flow constant. This turbulent injection resulted in the formation of a double emulsion (W 1 /O/ W 2 ), which was homogenized for 4 min. Later, the final emulsion was magnetically stirred to allow solvent evaporation and microparticles formation. The microparticles were centrifuged (9300 x g, 12150-H, Sigma 3K30) and washed with distilled water twice. Finally, the microparticles were freeze dried, lyophilized (Genesis 12EL, Virtis, USA) and stored at 4ºC for their conservation.
Besides, empty microparticles were fabricated in the same way as described above but without adding either ovalbumin or CpG sequences.
Microparticle characterization
The size of the particles was determined by laser diffractometry using a Mastersizer S laser sizer (Malvern Instruments, UK). The mean size was expressed as the volume mean diameter in micrometers (µm). Microparticles zeta potential was assessed by laser Doppler velocimetry in a Zetasizer Nano ZS (Malvern Instruments, UK). For these analyses, the samples were diluted in distilled water at room temperature and the measurements were performed in triplicate. 8 The yield of the preparation process was calculated as the difference between the initial amount of polymer used to fabricate the microparticles and the final weight of lyophilized samples, expressed as percentage (%).
The shape and morphology of the microparticles were evaluated by scanning electron microscopy. The samples were coated with a platinum/palladium layer (Cressington Sputter Coater 208 HR, UK) under argon atmosphere. The micrographs were obtained using a scanning electron microscope (LEO 1530, France).
The amount of OVA associated to the microparticles was calculated using the MicroBCA protein assay. Lyophilized microparticles (5 mg) were degraded with 1 mL of NaOH 0.1N under magnetic stirring at room temperature overnight. The samples were centrifuged (27100 x g, 10 min) and the resulting pellets were incubated with the MicroBCA reagent for 2 h at 37ºC. Then, the solutions were measured in a spectrophotometer (iEMS Reader MF, Labsystems, Finland) at 562 nm and compared with the absorbance data obtained with OVA in solution. For this purpose, calibration curves (1.5-50 µg/mL) were performed using control OVA dissolved in NaOH 0.1N.
Each sample was assessed in triplicate and the results were expressed as the amount of protein per milligram of microparticle. Besides, the encapsulation efficiency was defined as the percentage of OVA loaded relating to the initial amount of protein.
To determine the CpG sequences loading, 5 mg of microparticles were shaked with NaOH 0.1 overnight at room temperature. Oligreen ssDNA Quantitation reagent was added to the samples and the resulting fluorescence was measured at 522 nm (PerkinElmer LS 50B Luminiscence Spectrometer, USA). CpG motifs were dissolved in buffer TE in order to perform a sigmoidal-fitted calibration curve (0.05-1.5 µg/mL).
The results were expressed as the amount (in µg) of oligonucleotide per milligram of microparticle. Also, the entrapment efficiency was calculated as the ratio between the loaded and the initial quantity of CpG sequences, expressed in percentage (%).
In vitro release study
Microparticles containing OVA and/or CpG sequences (5 mg) were dispersed in 1 mL of phosphate buffer saline (PBS 0.15M, pH 7.4) in eppendorf tubes. Then, the samples were maintained under rotating agitation at 37ºC and at predetermined intervals, the eppendorf tubes were centrifuged at 27100 x g for 20 min (12150-H, Sigma 3K30). In the supernatants, the amount of OVA and CpG sequences released from the particles were determined as described above (MicroBCA protein assay and Oligreen ssDNA Quantitation kit, respectively). Meanwhile the pellets were resuspended in 1 mL of PBS. Empty microparticles were used as controls and subjected to the same procedure. Release data were expressed as the cumulative percentage of OVA and oligonucleotide released in comparison with the initial content of these molecules in the microparticles versus time.
Structural integrity and antigenicity of the entrapped OVA
Protein profile of encapsulated OVA and OVA released from the microparticles was determined by SDS-PAGE and its antigenicity by immunoblotting.
OVA loaded microparticles (5 mg) were dissolved in methylene chloride. The organic solvent was evaporated with nitrogen and the residue was suspended in electrophoretic sample buffer (TRIS-HCl 62.5 mM (pH 6.8), 10% glycerol, 2% SDS, 5% β-mercaptoethanol and 0.05% bromophenol blue). Then, the suspensions were centrifuged (2300 x g, 10 min) to remove polymeric residues. Afterwards, the samples were boiled during 10 min to separate possible ovalbumin degradation fragments.
For SDS-PAGE, samples were analysed by using 15% acrylamide slabs with the discontinuous buffer system of Laemmli [35] and gels stained with Coomasie Brilliant
Blue R-250 [36] . Immunoblotting was carried out as described previously [37] with immunoglobulin G against OVA from mouse and with horseradish conjugated rabbit anti-IgG, and 4-chloro, 1-naphtol as chromogen.
Integrity of CpG sequences
The integrity of CpG sequences after the preparative process and released from the microparticles was analysed by means of the determination of its melting temperature [38] . On one hand, the oligonucleotide was extracted from the particles using NaOH 0.1N under shaking overnight at room temperature. On the other hand, microparticles were incubated with PBS under rotating agitation at 37ºC to allow CpG sequences to be released for 35 days. Both solutions were adjusted to a concentration of 4 ng/µL and incubated with their complementary sense oligonucleotide in a ratio 1:1 in the presence of 1 µL of SYBR Green I nucleic acid gel stain diluted in buffer 100 mM Tris-HCl (pH 8.9), 100 mM NaCl and 14 mM MgCl2. Throughout the incubation period, sense and antisense oligonucleotides formed a double strand, which enclosed the SYBR Green I. This molecule emitted fluorescence when it is associated to the duplex and its signal is proportional to the hybridization capacity. This parameter was measured in a fluorescence temperature cycler (Lyghtcycler, Roche Diagnostics GmbH, Germany). Precisely, the duplex was heat at 0.2ºC/s to 95ºC measuring the fluorescence signal during the process and obtaining a melting curve. For improved visualisation of the melting temperature or T m (temperature at which 50% of the oligonucleotide is forming a double strand) the initial data were derived to obtain melting peaks (fluorescence (F) versus temperature (T) by plotting the negative derivative of fluorescence over temperature versus temperature; (-dF/dT) versus T).
Bone marrow-derived dendritic cells (BMDC) generation and activation
C57BL/6 mice (8 weeks, female) were obtained from Harlan Interfauna Ibérica (Spain) and housed in pathogen-free conditions according to the guidelines of the Ethical Committee of the University of Navarre in line with the European legislation on animal experiments (86/609/EU). As described before [39] , femurs and tibia were extracted after cervical dislocation and the bone marrow was flushed out using a 26 gauge needle with RPMI 1640 medium supplemented with 0.1% -mercaptoethanol 50 mM, 0.5% sodium pyruvate 100 mM, 1 IU/Ml penicillin, 1 µg/ml streptomycin and 10% v/v foetal bovine serum (all from Gibco-BRL, UK). After the lysis of the erythrocytes, the cell suspension was purified and deplected of lymphocytes and granulocytes by incubation with a mixture of antibodies against CD4, CD8, Ly-6G/Gr1 and CD45R and rabbit complement. The resulting solution was grown at 10 6 cells/mL in 6-well plates with RPMI 1640 medium containing GM-CSF and IL-4 (25 ng/mL; PrepoTech EC, UK). After confirming that the BMDC precursors were CD11c+, twothirds of the medium was replaced with fresh medium containing GM-CSF and IL-4 at days 2, 4, 5 and 6. Afterwards, CpG microparticles (2 µg/mL) were incubated for 24 h at 37ºC to evaluate their capability to induce BMDC maturation and the resulting supernatants were collected for IL-12 determination using a commercial ELISA kit (Pharmingen, BD Biosciences, USA). Free CpG and LPS used as controls and subjected to the same experimental conditions.
Mice immunization
Female BALB/c mice were purchased from Harlan Interfauna Ibérica (Spain), Blood samples were collected from the retro-orbital plexus at day 0, 14, 28, 35, 42 and 49 after the first immunization. The samples were centrifuged and the resulting sera were pooled. Finally, the sera were diluted 1:10 in PBS and stored at -80ºC until assayed by ELISA.
Measurement of anti-OVA antibody levels in serum
An indirect ELISA was performed to determine the level of OVA-specific antibody isotypes in the serum [40] . The experiment was carried out as follows: 96-well microtitre plates (Thermo Labsystems, Finland) were coated overnight with 1 µg per well of ovalbumin in carbonate-bicarbonate buffer (pH 9.6) and maintained at 4ºC.
After being washed in buffer (phosphate buffer saline containing 0.05% Tween ® 20, PBS-T20), serum samples (100 µl) at different dilutions were added to wells and incubated during 4 h at 37ºC. Then, unbound antibody was washed prior to the addition of 100 µl of goat anti-mouse IgG1 or IgG2a horseradish peroxidase conjugate (Nordic Immunology, Netherlands) diluted 1:1000 in PBS-T20 (37ºC, 1 h). After a final wash step, 100 µl of chromogen and substrate solution (2, 2 -Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid and hydrogen peroxide) was added. The plates were incubated at room temperature for 30 min, and, finally, the absorbance was measured at 405 nm by an iEMS Reader MF (Labsystems, Finland).
Cytokine assay
Naïve and immunized mice were sacrificed by cervical dislocation at day 13 after immunization and their spleens removed and placed in RPMI 1640 media (Gibco-BRL, UK) under sterile conditions. Each spleen was smashed and cells within experimental groups were pooled in one flask. The cellular suspension was centrifuged at 400 x g for 10 min, the supernatant discarded and the pellet washed twice with PBS.
The splenocytes were suspended in lysis buffer (NH 4 levels were determined using a commercial ELISA kit (Biosurce International, USA). µm and -5 mV, approximately), the CpG loading tended to decrease to the half (from 11.5±5.1 to 6.4 µg/mg) when the N/P ratio increased. Thus, the following microparticles batches were performed at fixed N/P ratio of 0.26.
Results
Optimization of CpG loading in microparticles
Microparticle characterization
CpG and/or OVA encapsulated microparticles were prepared using two types of PLGA copolymers, PLGA 502 and PLGA 756. Their differences in molecular weight and hidrophylicity could influence OVA and CpG loading, release and immune response. The results are summarized in for respectively OVA microparticles and OVA CpG microparticles). Finally, the amount of CpG sequences associated to the particles was close to 12 µg/mg microparticles and was independent on antigen co-encapsulation and polymer nature.
From SEM micrographs studies (Fig. 1 ), microparticles were found to be spherical, homogenous, without pores and with similar sizes than those obtained by laser diffractometry. 
OVA and CpG sequences release from the microparticles
OVA structural analysis and antigenicity and CpG integrity
The effect of the preparative process on both the structural integrity and antigenicity were studied by SDS-PAGE and immunoblotting, respectively (Fig. 3 ). All the formulations tested showed a similar band corresponding with the native protein (45 kDa) indicating that the integrity and the antigenicity was not altered following entrapment in any of the microparticle formulations. When studying these parameters in samples from release experiments, the structure and the antigenicity of the protein were unaltered in any of the formulations assessed (data not shown).
The integrity of the CpG sequences was determined by means of the melting temperature, which is related with the capability of the CpG strand to form a duplex. Fig. 4 shows the T m values for all the microparticles. As it can be observed, encapsulated CpG displayed a similar temperature comparing with free CpG sequences so the method of preparation did not modify the structure of the oligonucleotide. For the CpG sequences released from the microparticles, the T m values were similar than the one obtained for free oligonucleotide (data not shown). Therefore, the integrity of the encapsulated oligonucleotide was maintained throughout the release studies.
Activation of immature DC by CpG loaded microparticles
IL-12 production was determined to evaluate if CpG microparticles were able to induce immature DC functional activation (Fig. 5 ). This cytokine level was assessed after incubation at two different CpG concentrations, 0.5 and 1 µg/mL. The IL-12 produced after incubation with CpG microparticles was slightly higher (14512.5 and 13487.5 pg/mL for CpG PLGA 756 and 502 microparticles, respectively, at 1 g/mL) than the one produced by CpG sequences in solution (8241.2 pg/mL at 1 g/mL) at any CpG concentrations.
Antibody response
IgG1 and IgG2a antibodies levels were studied in BALB/c mice immunized at days 0 and 7 with 10 µg OVA or the equivalent amount of microparticles ( Fig. 6 and 7 ).
The administration of OVA loaded PLGA 756 enhanced the antibodies production (15 
Discussion
This work aimed at the preparation of CpG and a model shed antigen (ovalbumin) loaded microparticles by a new double emulsion solvent evaporation method called "Total Recirculation One-Machine System" (TROMS). In the recent past,
we have shown the performance of this novel technique for loading adenoviruses [41] , plasmid DNA [33] and Brucella antigens [34] without compromise their integrity. In this study, TROMS is used for achieving non charged microparticles with high antigen and CpG pay-loads and avoiding destruction of the protein and CpG oligonucleotides.
The immunogenicity of these formulations was evaluated in BALB/c mice and compared with the co-administration of soluble forms of CpG and antigen.
The improvement of CpG stimulatory potency by liposomes or microparticles based delivery has been clearly established [42] [43] [44] . Nearly all of these reports are based on the absorption of CpG onto preformed positive particles except for few works which tested the adjuvant effect inside the polymeric matrix with more [25] or less [45] success. In another context, some studies have applied for the complexation of CpG oligonucleotides or CpG DNA with positive molecules (such as PEI [31] or DOTAP) to modify the intracellular uptake and route with negative or positive effect in their stimulatory activity. In the current study, we investigated the immune response induced by the co-delivery of CpG-chitosan complexes (not characterized in this research work) and OVA in non-charged PLGA microspheres. In first trials, we recorded several cationic molecules (data not shown) and chitosan was almost the only one (i) suitable for adequate loading of CpG into PLGA particles and (ii) that did not have negative effect in CpG stimulatory potency, evaluated as IL-12 production by BMDC in vitro (data not shown). As compared with other works [25, 32, 46] , it is remarkable that TROMS methodology loaded appreciable amounts of CpG motifs onto around 1 µm PLGA particles that did not exhibit positive zeta potential because of low chitosan percentage (lower than 0.1% w/w) ( Table 2 ). Several attempts, concerning the amount of chitosan included in the formulation, were carried out to obtain higher CpG encapsulation efficiency. Unfortunately, the more presence of chitosan in the microparticles could lead to an excess of viscosity inducing a potent instability of the inner aqueous phase and reducing the CpG encapsulation. In this context, the included chitosan could be insufficient to ensure the total complexation of the oligonucleotide.
Consequently, it is possible to expect that certain CpG molecules would not associate with the cation reducing their potential loading. Also, similarly that previously reported with other antigens [33, 34] , TROMS microencapsulated the antigen, OVA, with high efficiency whereas OVA antigenic properties were maintained (Fig. 3) , also during sustained release periods (data not shown). The integrity of CpG molecules was also preserved during the preparative process as long as T m values remained unchanged (Fig.   4 ).
There are some factors that can affect the immune response elicited by the administration of microencapsulated antigens. Among them, the polymer type has been shown able to modify the antigen intrinsic cytokine profile [47, 48] . In the current study mice were immunized with two different formulations containing PLGA756 or PLGA502 as the polymers. Whereas OVA alone or OVA loaded into PLGA502 microparticles triggered IgG1 antibody response, OVA microencapsulated into PLGA756 displayed higher antibody titers and increased production of IgG2a antibodies ( Fig. 6 and 7) , accompanied by strong IFN-γ production. This fact could be explained by the more enhanced interaction between hydrophobic polymers (such as PLGA 756) and antigen presenting cells, and, consequently, the promotion of the Th activation [49] .
The ability of CpG ODN to trigger the production of T-helper 1 and proinflammatory cytokines and IFN-dependent IgG2a antibodies has been observed with a variety of co-administered antigens [50] [51] [52] [53] . This adjuvant effect was clearly dose dependent and mediated by cytokines produced following stimulation of APC, as for example, IL-12.
The co-association of CpG ODN or CpG DNA with antigens in delivery systems have been previously shown to be very more effective to elicit specific T cell response that CpG simply co-administered with antigen and also that induced by the administration of the antigens microencapsulated alone. On the contrary, the immunopotentiation effect of the particulate delivery on antibody response has not been clearly established. For the first time, our data give clear evidence of the critical influence of PLGA polymer in particulate CpG adjuvanticity and clear differences between both arms of the adaptive immunity.
CpG motifs co-encapsulated into PLGA 502 induced higher antibodies titres and increased production of IgG2a antibodies that OVA microencapsulated alone, being more effective that both co-administered freely in solution ( Fig.6 and 7) . On the contrary, co-delivery of CpG and OVA in PLGA 756 microparticles decreased IgG2a antibodies levels. Previous studies gave explanations for both, increase or decrease of antibody response when CpG was delivery into particles. So, nanoparticles that loaded CpG inside their matrix could release CpG in a sustained manner that resulted in suboptimal doses for B cell stimulation [45] . On the contrary, CpG presented onto the surface of cationic microspheres was able to augment the antibody response and it was suggested due to a certain effect of surface nature in B cells engagement [28, 32] . CpG administration [24, 25, 42, 54] . So far, the absence of correlation with the observed antibodies production could be due to the direct effect of CpG oligonucleotide in B cells. Also, the cellular response was determined after one immunization whereas the antibodies levels were evaluated after two administrations (prime and boost). Other authors have reported differences in antibodies subtypes induced by CpG ODN when given in the primary immunization and/or in the boosting [55] .
In summary, our results established the critical role of PLGA microparticle characteristics, i.e. the hydrophobicity of the polymer used, in the antigen-specific 24 adjuvanticity of encapsulated CpG motifs. Although further studies should be carried out to characterise chitosan-CpG complex, this combination of molecules into microparticles succeeds in high encapsulation efficiencies of both the antigen and the oligonucleotide which would avoid multiple injection schedule and its possible sideeffects. Free CpG (light grey) and LPS (first column) were used as control and subjected to the same experimental conditions. 
